Stock SYNCOMF SYNCOM FORMULATIONS (INDIA) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Syncom Formulations (India) Limited

Equities

SYNCOMF

INE312C01025

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:48 2024-05-17 EDT 		5-day change 1st Jan Change
13.44 INR -0.59% Intraday chart for Syncom Formulations (India) Limited +2.99% -10.64%
03-29 Syncom Formulations Limited Announces Board Changes CI
02-14 Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Valuation

Fiscal Period: Maart 2018 2019 2020 2021 2022 2023
Capitalization 1 757.2 843.1 562.1 2,449 9,168 5,546
Enterprise Value (EV) 1 822.6 851.3 497.8 2,334 9,328 5,669
P/E ratio 8.08 x 7.71 x 4.24 x 8.38 x 46.9 x 27.3 x
Yield - - - - 0.28% -
Capitalization / Revenue 0.48 x 0.45 x 0.27 x 1 x 4.17 x 2.47 x
EV / Revenue 0.52 x 0.46 x 0.24 x 0.95 x 4.25 x 2.53 x
EV / EBITDA 7.06 x 7.22 x 3 x 6.17 x 50.1 x 28.9 x
EV / FCF -8.46 x 11.1 x 12.8 x -48.4 x 215 x -53.9 x
FCF Yield -11.8% 9.02% 7.84% -2.07% 0.46% -1.85%
Price to Book 0.62 x 0.64 x 0.39 x 1.31 x 4.13 x 2.17 x
Nbr of stocks (in thousands) 780,652 780,652 780,652 789,952 862,453 940,000
Reference price 2 0.9700 1.080 0.7200 3.100 10.63 5.900
Announcement Date 18-09-01 19-08-30 20-09-03 21-09-04 22-08-27 23-09-04
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Maart 2018 2019 2020 2021 2022 2023
Net sales 1 1,586 1,868 2,055 2,448 2,197 2,243
EBITDA 1 116.5 117.9 166.1 378.1 186 196.5
EBIT 1 79.43 78.13 125.8 338 154.1 152.2
Operating Margin 5.01% 4.18% 6.12% 13.81% 7.02% 6.79%
Earnings before Tax (EBT) 1 120.1 126.8 172.9 407 261.8 265.7
Net income 1 86.47 110.9 142.5 291.7 197.9 200.7
Net margin 5.45% 5.94% 6.94% 11.92% 9.01% 8.95%
EPS 2 0.1200 0.1400 0.1700 0.3700 0.2267 0.2162
Free Cash Flow 1 -97.19 76.82 39.03 -48.25 43.3 -105.1
FCF margin -6.13% 4.11% 1.9% -1.97% 1.97% -4.69%
FCF Conversion (EBITDA) - 65.17% 23.5% - 23.27% -
FCF Conversion (Net income) - 69.27% 27.38% - 21.88% -
Dividend per Share - - - - 0.0300 -
Announcement Date 18-09-01 19-08-30 20-09-03 21-09-04 22-08-27 23-09-04
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 65.4 8.15 - - 160 123
Net Cash position 1 - - 64.2 115 - -
Leverage (Debt/EBITDA) 0.5613 x 0.0691 x - - 0.8605 x 0.6253 x
Free Cash Flow 1 -97.2 76.8 39 -48.2 43.3 -105
ROE (net income / shareholders' equity) 7.23% 8.71% 10.2% 17.5% 9.66% 8.39%
ROA (Net income/ Total Assets) 2.83% 2.84% 4.45% 8.95% 3.21% 2.77%
Assets 1 3,058 3,906 3,204 3,260 6,161 7,238
Book Value Per Share 2 1.560 1.700 1.870 2.370 2.580 2.720
Cash Flow per Share 2 0.0100 0.0900 0.1100 0.0300 0 0.0100
Capex 1 66.3 - 17.5 - 113 206
Capex / Sales 4.18% - 0.85% - 5.15% 9.2%
Announcement Date 18-09-01 19-08-30 20-09-03 21-09-04 22-08-27 23-09-04
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
SYNCOM FORMULATIONS (INDIA) LIMITED Stock Syncom Formulations (India) Limited
-10.64% 152M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.36% 694B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.72% 593B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.60% 371B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.07% 331B
ABBVIE INC. Stock AbbVie Inc.
+6.04% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.53% 239B
ROCHE HOLDING AG Stock Roche Holding AG
-3.15% 209B
NOVARTIS AG Stock Novartis AG
+10.09% 209B
AMGEN INC. Stock Amgen Inc.
+9.27% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SYNCOMF Stock
  4. Financials Syncom Formulations (India) Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW